Theracryf PLC - Successful GMP Manufacture Advances Ox-1 to Clinic

TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Lead Asset Ox-1 Advances Towards Clinic With Successful GMP Manufacture For Human Use
Over 2kg of clinical-grade material produced to support Phase 1 trials
TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces the successful manufacture of over 2kg of drug substance for its lead orexin-1 (Ox-1) receptor antagonist to Good Manufacturing Practice (GMP) standard. Generating human-grade material that meets regulatory standards is the vital next step following the Company's manufacturing update on
This critical milestone enables a seamless transition from preclinical to clinical activity, allowing initiation of dosing in humans after approval to conduct the Phase 1 study, without introducing programme delays due to further manufacturing.
TheraCryf's manufacturing partner successfully produced 2.57kg of human-grade drug substance in an efficient process with a higher yield than anticipated, delivering three weeks ahead of schedule and confirming the scalability and robustness of the Company's optimised manufacturing process, which is the subject of a recent patent filing.
Efficient GMP manufacturing is often a key bottleneck in drug development, leading to delays and higher product costs. In contrast, TheraCryf's Ox-1 antagonist has been successfully manufactured at scale, with clinical trial material meeting all required quality standards on first pass, supporting the planned Phase 1 study in human volunteers. This demonstrates strong process reliability, further de-risking the programme as it advances towards clinic readiness.
The drug substance is now ready for formulation into the final drug product that will be given to the Phase 1 volunteers. Completion of the preclinical package, including delivery of the 28-day toxicology study results, the final step to enable a regulatory submission and clinic readiness, remains on schedule for Q3 2026.
Ox-1 is being developed for the treatment of substance use disorders, a large and growing global market projected to exceed
Dr
"Achieving successful GMP manufacture of human-grade Ox-1 drug substance is an important milestone that further de-risks the programme as we move towards the clinic. The fact that the manufacturing process has proven robust and reliable, with good yields, enhances the commercial attractiveness of our Ox-1 antagonist.
Combined with our recent positive preclinical data and the filing of a new patent, this progress reinforces our confidence in Ox-1 as a potentially best-in-class treatment for addiction, a market that will be worth over
With toxicology studies underway and on schedule, we remain focused on advancing towards first-in-human studies and moving the programme towards accretive partnership opportunities with commercially focused pharmaceutical companies."
1. Substance Use Disorder Treatment Market Size and Share Forecast Outlook 2025 to 2035. Future Market Insights Inc,
-Ends-
Enquiries
|
TheraCryf plc Dr Dr
|
+44 (0)1625 315 090 |
|
Singer Capital Markets (NOMAD & Joint Broker)
|
+44 (0)20 7496 3000 |
|
Turner Pope Investments (Joint Broker)
|
+44 (0)20 3657 0050
|
|
Northstar Communications (Investor Relations) |
+44 (0)113 730 3896 sarah@northstarcommunications.co.uk
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders.
The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf's headquarters and registered office are at Alderley Park,
For further information, visit: https://theracryf.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE